诱导缓解期早期疗效评估在中间核型急性髓系白血病的预后价值(2)
 |
| 第1页 |
参见附件。
[3]Avivi I, Rowe JM. Prognostic factors in acute myeloid leukemia [J]. Curr Opin Hematol, 2004; 12:62–67.
[4]Grosicki S, Holowiecki J, Giebel S, et al. The early reduction of leukemic blasts in bone marrow on day 6 of induction treatment is predictive for complete remission rate and survival in adult acute myeloid leukemia; The results of multicenter, prospective Polish Adult Leukemia Group Study [J]. Am J Hematol, 2011; 86:437-439.
[5]Xiao Z, Xue H, Li R, et al. The prognostic significance of leukemic cells clearance kinetics evaluation during the initial course of induction therapy with HAD (homoharringtonine, cytosine arabinoside, daunorubicin) in patients with de novo acute myeloid leukemia [J].Am J Hematol, 2008; 83: 203-205.
[6]Haferlach T, Kern W, Schoch C, et al. A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group [J]. Haematologica, 2004; 89(4):408-418.
[7]Heil G, Krauter J, Raghavachar A, et al. Risk-adapted induction and consolidation therapy in adults with de novo AML aged≤60 years: results of a prospective multicenter trial [J]. Ann Hematol, 2004; 83:336–344.
[8]Mrzek K, Marucci G, Paschka P, et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification [J] ？Blood, 2007; 109: 431-448.
[9]Grimwade D, Vyasb P , Freeman S, et al. Current Assessment of minimal residual disease in acute myeloid leukemia[J].Opinion in Oncology, 2010; 22:656–663.
您现在查看是摘要介绍页，详见PDF附件(2262kb)。